search
Back to results

A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX) (METROmaJX)

Primary Purpose

Solid Tumors, Soft-tissue Sarcoma, Breast Cancer

Status
Recruiting
Phase
Phase 1
Locations
France
Study Type
Interventional
Intervention
Cyclophosphamide and JX-594 dose escalation
Cyclophosphamide and JX-594
Cyclophosphamide
Avelumab and JX-594 and Cyclophosphamide
Sponsored by
Institut Bergonié
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Solid Tumors focused on measuring Advanced Soft-tissue Sarcoma, Advanced Breast Cancer, Maximum Tolerated Dose, Efficacy and safety, Immunotherapy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Main Inclusion Criteria:

  1. Histology:

    • Phase Ib : Patient with histologically confirmed solid tumor
    • Phase II :

      • Patients with histologically confirmed HER2 negative breast cancer (treatment by CP+JX-594), or triple negative (treatment by avelumab + CP+JX-594)
      • Patients with histologically confirmed soft tissue sarcoma confirmed by the RRePS Network, b)Progressive disease or relapse, after standard therapy according to RECIST v1.1 criteria diagnosed on the basis of two CT scan or MRI obtained at an interval less than 6 months in the period of 12 months prior to inclusion and confirmed by central review
  2. Metastatic or unresectable locally advanced disease
  3. Age ≥ 18 years
  4. ECOG ≤ 1 (Phase Ib), ≤ 2 (Phase II JX+CP) and ≤ 1 (Phase II avelumab+JX+CP).
  5. Life expectancy > 3 months,
  6. Measurable disease according to RECIST v1.1 outside any previously irradiated field. For patients treated by avelumab+JX+CP, at least one injectable site ≥ 2 cm and ≤ 8 cm in diameter and one distant non-injected measurable site (target site)
  7. At least three weeks since last chemotherapy, immunotherapy or any other pharmacological treatment and/or radiotherapy.
  8. Adequate hematological, renal, metabolic and hepatic functions.
  9. Women of childbearing potential must have a negative serum pregnancy test before study entry. Both women and men must agree to use a medically acceptable method of contraception throughout the treatment period and for six months after discontinuation of treatment.
  10. Patients informed of risks regarding drug interactions: patients receiving any substances that are inhibitors or inducers of CYP450 2B6 are ineligible
  11. Voluntarily signed and dated written informed consent prior to any study specific procedure.
  12. Patients with a social security in compliance with the French law.

Main Exclusion Criteria:

  1. Previous treatment with JX-594 or other vaccina vector based treatment .
  2. Concomitant diseases/conditions (non exhaustive list):

    1. Clinically significant immunodeficiency, such as HIV or active Hepatite B or C
    2. Any other major illness that, in the Investigator's judgment, will substantially increase the risk associated with the patient's participation in this study.
    3. History of severe exfoliative skins condition requiring systemic treatment for more than 4 weeks in the last two years.
    4. active autoimmune disease for patients treated by avelumab
  3. Active central nervous system metastasis (CNS)
  4. Participation to a study involving a medical or therapeutic intervention in the last 30 days.
  5. Previous enrolment in the present study.
  6. Patient unable to follow and comply with the study procedures because of any geographical, social or psychological reasons.
  7. Known hypersensitivity to any involved study drug or any of its formulation components.
  8. Use of steroids (any route of administration), interferon/pegylated interferon or ribavirin that cannot be discontinued within 14 days prior to any JX-594 dose.
  9. No prior malignancy except for the following: adequately treated basal or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage 1 or Stage 2 cancer from which the patient is currently in complete remission or any other cancer from which the patient has been disease-free for 3 years.
  10. Active cardiovascular disease, including but not limited to significant coronary artery disease (e.g. requiring angioplasty or stenting) or congestive heart failure within the preceding 12 months. (treatment by CP+JX)
  11. Inability to suspend treatment with anti-hypertensive medication for 48 hours prior to and 48 hours after all JX-594 treatments.
  12. Pulse oximetry O2 saturation < 90% at rest on room air.
  13. Experienced a severe systemic reaction or side-effect as result of previous smallpox vaccination.
  14. Cardiac disease: LVEF out of normal limits ; cumulative dose of anthracyclines in excess of 450 mg/m²
  15. Known urinary tract obstruction
  16. Household contact exclusions for patients enrolled: children< 1 year old ; People with skin disease (e.g., eczema, atopic dermatitis and related diseases…), Immunocompromised hosts (severe deficiencies in cell-mediated immunity, including AIDS, organ transplant recipients, hematologic malignancies)
  17. Vaccination within 4 weeks of the first dose of study treatment and while on trial is prohibited except for administration of inactivated vaccines.

Sites / Locations

  • Institut BergonieRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

Experimental phase I dose escalating

Experimental group soft-tissue sarcoma, treatment by JX-594 + Metronomic cyclophosphamide

Control group soft-tissue sarcoma, treatment by JX-594 + Metronomic cyclophosphamide

Experimental group breast cancer, treatment by JX-594 + Metronomic cyclophosphamide

Experimental group soft-tissue sarcoma, treatment by Avelumab + ITJX-594 + Metronomic CP

Experimental group breast cancer, treatment by Avelumab + IT JX-594 + Metronomic CP

Arm Description

Prospective open-labeled phase I trial. Combination of cyclophosphamide and JX-594 dose escalation. Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as designated by assigned dose-level, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days. Number of subjects : 14

Randomized non comparative phase II clinical trial : Arm 1. Experimental phase II soft-tissue sarcoma : Combination of cyclophosphamide and JX-594. Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as the dose recommended in the experimental phase I dose escalating study, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days. Number of subjects : 48

Randomized non comparative phase II clinical trial : Arm 2. Control-arm phase II soft-tissue sarcoma : Patients will be treated by metronomic cyclophosphamide. Cyclophosphamide will be administered 50 mg twice daily orally, one week on/one week off. One cycle consits of 28 days. Number of subjects : 24

Single-arm phase II clinical trial. Experimental phase II Group breast cancer : Combination of cyclophosphamide and JX-594. Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as the dose recommended in the experimental phase I dose escalating study, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days. Number of subjects : 32

Experimental phase II soft-tissue sarcoma : Combination of avelumab in combination with intratumoral JX-594 and metronomic cyclophosphamide. Avelumab will be administered by intravenous infusion every 2 weeks, starting at Day 15 of cycle 1. Cyclophosphamide wil be administered orally, 50 mg twice daily, one Week on/one Week off, starting 7 days prior to cycle 1 day 1 ("impregnation phase"). JX-594 will be administered by intratumoral injection on day 1 of cycle 1, every 2 weeks, for a maximum of 4 injections. Number of subjects : 47

Experimental phase II breast cancer : Combination of avelumab in combination with intratumoral JX-594 and metronomic cyclophosphamide. Avelumab will be administered by intravenous infusion every 2 weeks, starting at Day 15 of cycle 1. Cyclophosphamide wil be administered orally, 50 mg twice daily, one Week on/one Week off, starting 7 days prior to cycle 1 day 1 ("impregnation phase"). JX-594 will be administered by intratumoral injection on day 1 of cycle 1, every 2 weeks, for a maximum of 4 injections. Number of subjects : 32

Outcomes

Primary Outcome Measures

Phase Ib : Maximum Tolerated Dose evaluated on the first cycle (D1 to D28) of the combination of JX-594 And metronomic cyclophosphamide
the MTD is defined as the highest dose at which no more than 1 in 6 of the patients in the cohort experienced a DLT in the first treatment cycle
Phase II : Advanced soft-tissue sarcoma: Assessment of the antitumor activity of the association of JX-594 and metronomic cyclophosphamide based on 6 month non-progression (CR, PR or SD more than 24 weeks) following RECIST v1.1 criteria
Non-progression is defined as complete or partial response or stable disease, as per RECIST v1.1
Phase II : Advanced Breast cancer: Assessment of the antitumor activity of the association of JX-594 and metronomic cyclophosphamide Efficacy will be defined based on objective response under treatment (CR or PR) following RECIST v1.1 criteria
Objective response is defined as complete or partial response as per RECIST v1.1
Phase II : Advanced soft-tissue sarcoma: Assessment of the antitumor activity of Avelumab in combination with IT JX-594 and metronomic cyclophosphamide based on 6 month non-progression (CR, PR or SD more than 24 weeks) following RECIST v1.1 criteria
Non-progression is defined as complete or partial response or stable disease, as per RECIST v1.1
Phase II : Advanced Breast cancer: Assessment of the antitumor activity of avelumab in combination with IT JX-594 and metronomic cyclophosphamide Efficacy will be defined based on objective response under treatment following RECIST v1.1 criteria
Objective response is defined as complete or partial response as per RECIST v1.1

Secondary Outcome Measures

Phase Ib : Recommended Phase II dose (RP2D) of the association of JX-594 and metronomic cyclophosphamide
Data from all cycles will be used to define the dose level of JX-594 to be recommended for further investigations in phase II
Phase Ib: Objective response under treatment as per RECIST V1.1
Objective response is defined as complete or partial response as per RECIST v1.1
Phase Ib: Best overall response as per RECIST V1.1
- Best overall response is defined as the best response recorded from the start of the study treatment until the end of treatment taking into account any requirement for confirmation (as per RECIST v1.1).
Phase Ib: 6-months non-progression as per RECIST V1.1
Non-progression is defined as complete or partial response or stable disease, as per RECIST v1.1
Phase Ib: 1-year progression-free survival as per RECIST V1.1
PFS defined as the time from study treatment initiation to the first occurrence of disease progression or death (of any cause)
Phase Ib: 2-year progression-free survival as per RECIST V1.1
PFS defined as the time from study treatment initiation to the first occurrence of disease progression or death (of any cause)
Phase Ib : Pharmacokinetics (PK): PK measurements expressed as Area Under the curve forJX-594
Phase Ib : Pharmacokinetics (PK): PK measurements expressed as half-life forJX-594
Phase Ib : Pharmacokinetics (PK): PK measurements expressed as Concentration peak forJX-594
Phase Ib : Dose-Limiting toxicity of the association of JX-594 and metronomic cyclophosphamide
Phase Ib : Predictive biomarkers analysis (cytokines levels)
Phase Ib : Predictive biomarkers analysis (lymphocytes levels)
Phase II : Best overall response defined as per RECIST v1.1 criteria
Best overall response is defined as the best response recorded from the start of the study treatment until the end of treatment taking into account any requirement for confirmation (as per RECIST v1.1).
Phase II : For sarcoma only: objective response following CHOI criteria
Phase II : For sarcoma only: best overall response following CHOI criteria
Phase II : For sarcoma only: 6- month non-progression following CHOI criteria
Phase II : 1-year Progression-Free Survival (PFS) defined as the time from study treatment initiation to the first occurrence of disease progression or death (of any cause), whichever occurs first
PFS defined as the time from study treatment initiation to the first occurrence of disease progression or death (of any cause)
Phase II : 2-year Progression-Free Survival (PFS) defined as the time from study treatment initiation to the first occurrence of disease progression or death (of any cause), whichever occurs first
PFS defined as the time from study treatment initiation to the first occurrence of disease progression or death (of any cause)
Phase II : 1-year Overall Survial (OS) defined as the time from study treatment initiation to death (of any cause)
OS defined as the time from study treatment initiation to death (of any cause)
Phase II : 2-year Overall Survial (OS) defined as the time from study treatment initiation to death (of any cause)
OS defined as the time from study treatment initiation to death (of any cause)
Phase II : Toxicity graded using the common toxicity criteria from the NCI v4.0
assessef with NCI-CTCAE V4
Predictive biomarkers (cytokines level)
Predictive biomarkers (lymphocytes level)
Phase II : Relationship between levels of anti-JX-594 antibodies and efficacy of CP + JX-594 in terms of 6-month non progression for sarcoma (as per RECIST V1.1)
Phase II : Relationship between levels of anti-JX-594 antibodies and efficacy of CP + JX-594 in terms of objective response for breast cancer (as per RECIST V1.1)
Phase II : Relationship between activation of the pRB/E2F/TK pathway and efficacy of CP + JX-594 on available archived tumor tissue in terms of 6- month non progression for sarcoma (as per RECIST V1.1)
Phase II : Relationship between activation of the pRB/E2F/TK pathway and efficacy of CP + JX-594 on available archived tumor tissue in terms objective response for breast cancer (as per RECIST V1.1)
Phase II Soft-tissue sarcoma: antitumor actiivty of avelumab in combination with IT JX-594 and metronomic CP in terms of best overall response
- Best overall response is defined as the best response recorded from the start of the study treatment until the end of treatment taking into account any requirement for confirmation (as per RECIST v1.1)
Phase II Breast cancer: antitumor actiivty of avelumab in combination with IT JX-594 and metronomic CP in terms of best overall response
- Best overall response is defined as the best response recorded from the start of the study treatment until the end of treatment taking into account any requirement for confirmation (as per RECIST v1.1)
Phase II Breast cancer: antitumor actiivty of avelumab in combination with IT JX-594 and metronomic CP in terms of 6-month non-progression
Non-progression is defined as complete or partial response or stable disease, as per RECIST v1.1
Phase II Soft-tissue sarcoma: antitumor actiivty of avelumab in combination with IT JX-594 and metronomic CP in terms of objective response Under treatment
Objective response is defined as complete or partial response as per RECIST v1.1
Phase II Soft-tissue sarcoma: antitumor actiivty of avelumab in combination with IT JX-594 and metronomic CP in terms of 1-year progression-free survival
PFS defined as the time from study treatment initiation to the first occurrence of disease progression or death (of any cause)
Phase II Breast cancer: antitumor actiivty of avelumab in combination with IT JX-594 and metronomic CP in terms of 1-year progression-free survival
PFS defined as the time from study treatment initiation to the first occurrence of disease progression or death (of any cause)
Phase II Soft-tissue sarcoma: antitumor actiivty of avelumab in combination with IT JX-594 and metronomic CP in terms of 2-year progression-free survival
PFS defined as the time from study treatment initiation to the first occurrence of disease progression or death (of any cause)
Phase II Breast cancer: antitumor activity of avelumab in combination with IT JX-594 and metronomic CP in terms of 2-year progression-free survival
PFS defined as the time from study treatment initiation to the first occurrence of disease progression or death (of any cause)
Phase II Soft-tissue sarcoma: antitumor activity of avelumab in combination with IT JX-594 and metronomic CP in terms of 1-year overall survival
OS defined as the time from study treatment initiation to death (of any cause)
Phase II Breast cancer: antitumor activity of avelumab in combination with IT JX-594 and metronomic CP in terms of 1-year overall survival
OS defined as the time from study treatment initiation to death (of any cause)
Phase II Soft-tissue sarcoma: antitumor activity of avelumab in combination with IT JX-594 and metronomic CP in terms of 2-year overall survival
OS defined as the time from study treatment initiation to death (of any cause)
Phase II Breast cancer: antitumor activity of avelumab in combination with IT JX-594 and metronomic CP in terms of 2-year overall survival
OS defined as the time from study treatment initiation to death (of any cause)
Phase II Soft-tissue sarcoma: safety profile of avelumab in combination with IT JX-594 and metronomic CP
Safety profile will be assessed as per NCI-CTCAE v5
Phase II breast cancer: safety profile of avelumab in combination with IT JX-594 and metronomic CP
Safety profile will be assessed as per NCI-CTCAE v5

Full Information

First Posted
November 19, 2015
Last Updated
February 1, 2022
Sponsor
Institut Bergonié
Collaborators
National Cancer Institute, France, Fondation ARC, Merck Sharp & Dohme LLC, Transgene
search

1. Study Identification

Unique Protocol Identification Number
NCT02630368
Brief Title
A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX)
Acronym
METROmaJX
Official Title
A Phase I/II Study of Metronomic Cyclophosphamide and Oncolytic Poxvirus JX-594 in Patients With Advanced Hormone-receptor Positive and Triple Negative Breast Cancer and Advanced Soft Tissue Sarcoma (METROmaJX)
Study Type
Interventional

2. Study Status

Record Verification Date
January 2022
Overall Recruitment Status
Recruiting
Study Start Date
September 18, 2015 (Actual)
Primary Completion Date
May 2023 (Anticipated)
Study Completion Date
November 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Institut Bergonié
Collaborators
National Cancer Institute, France, Fondation ARC, Merck Sharp & Dohme LLC, Transgene

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Assessment of the efficacy and safety of JX-594 and metronomic cyclophosphamide in patients with advanced soft-tissue sarcoma and advanced breast cancer, once the Maximum Tolerated Dose have been determined (phase I trial). Phase I study: this is a prospective open-labeled phase I trial based on a dose escalating study design assessing two dose levels of JX594 when prescribed in combination with metronomic cyclophosphamide. Phase II trials with two treatments strategies: Metronomic CP + JX-594: phase II study sarcoma: this is a monocentric, randomized two-arm non comparative phase 2 study assessing efficacy and safety of JX-594 in association with metronomic cyclophosphamide in patients with advanced soft-tissue sarcoma. Metronomic CP + JX-594: phase II study breast cancer: this is a monocentric, single-arm phase II study, assessing efficacy and safety of JX-594 in association with metronomic cyclophosphamide in patients with advanced breast cancer. Metronomic CP + JX-594 + Avelumab: phase II study sarcoma: this is a monocentric, single arm phase II study assessing efficacy and safety of avelumab in combination with IT JX-594 and metronomic cyclophosphamide in patients with advanced soft-tissue sarcoma. Metronomic CP + JX-594 + Avelumab:: phase II study breast cancer: this is a monocentric, single-arm phase II study, assessing efficacy and safety of avelumab in combination with IT JX-594 and metronomic cyclophosphamide in patients with advanced breast cancer.
Detailed Description
For the phase I study, this is a prospective open-label phase I trial based on a dose escalating study design assessing two dose level of JX-594 when associated to metronomic cyclophosphamide. For the phase II study, two distincts treatment strategies will be evaluated. First, treatment by JX-594 and metronomic cyclophosphamide: stratum soft-tissue sarcoma, this is a monocenter, randomized non comparative phase II clinical trial. This phase II trial was based on an optimal 2-stage Simon's design. Randomization 2:1 with 2 patients randomized in experimental arm n°1 (association of metronomic cyclophosphamide and JX-594) and 1 patient randomized in control arm n°2 (treatment by metronomic cyclophosphamide alone). stratum breast cancer, this is a monocenter, one-arm phase II clinical trial, based on two-stage optimal Simon's design (association of metronomic cyclophosphamide and JX-594). Second, treatment by Avelumab, intratumoral JX-594 and metronomic cyclophosphamide: stratum soft-tissue sarcoma, this is a monocenter, single arm phase II clinical trial based on an optimal 2-stage Simon's design. stratum breast cancer, this is a monocenter, one-arm phase II clinical trial, based on two-stage optimal Simon's design).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Solid Tumors, Soft-tissue Sarcoma, Breast Cancer
Keywords
Advanced Soft-tissue Sarcoma, Advanced Breast Cancer, Maximum Tolerated Dose, Efficacy and safety, Immunotherapy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
197 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Experimental phase I dose escalating
Arm Type
Experimental
Arm Description
Prospective open-labeled phase I trial. Combination of cyclophosphamide and JX-594 dose escalation. Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as designated by assigned dose-level, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days. Number of subjects : 14
Arm Title
Experimental group soft-tissue sarcoma, treatment by JX-594 + Metronomic cyclophosphamide
Arm Type
Experimental
Arm Description
Randomized non comparative phase II clinical trial : Arm 1. Experimental phase II soft-tissue sarcoma : Combination of cyclophosphamide and JX-594. Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as the dose recommended in the experimental phase I dose escalating study, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days. Number of subjects : 48
Arm Title
Control group soft-tissue sarcoma, treatment by JX-594 + Metronomic cyclophosphamide
Arm Type
Experimental
Arm Description
Randomized non comparative phase II clinical trial : Arm 2. Control-arm phase II soft-tissue sarcoma : Patients will be treated by metronomic cyclophosphamide. Cyclophosphamide will be administered 50 mg twice daily orally, one week on/one week off. One cycle consits of 28 days. Number of subjects : 24
Arm Title
Experimental group breast cancer, treatment by JX-594 + Metronomic cyclophosphamide
Arm Type
Experimental
Arm Description
Single-arm phase II clinical trial. Experimental phase II Group breast cancer : Combination of cyclophosphamide and JX-594. Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as the dose recommended in the experimental phase I dose escalating study, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days. Number of subjects : 32
Arm Title
Experimental group soft-tissue sarcoma, treatment by Avelumab + ITJX-594 + Metronomic CP
Arm Type
Experimental
Arm Description
Experimental phase II soft-tissue sarcoma : Combination of avelumab in combination with intratumoral JX-594 and metronomic cyclophosphamide. Avelumab will be administered by intravenous infusion every 2 weeks, starting at Day 15 of cycle 1. Cyclophosphamide wil be administered orally, 50 mg twice daily, one Week on/one Week off, starting 7 days prior to cycle 1 day 1 ("impregnation phase"). JX-594 will be administered by intratumoral injection on day 1 of cycle 1, every 2 weeks, for a maximum of 4 injections. Number of subjects : 47
Arm Title
Experimental group breast cancer, treatment by Avelumab + IT JX-594 + Metronomic CP
Arm Type
Experimental
Arm Description
Experimental phase II breast cancer : Combination of avelumab in combination with intratumoral JX-594 and metronomic cyclophosphamide. Avelumab will be administered by intravenous infusion every 2 weeks, starting at Day 15 of cycle 1. Cyclophosphamide wil be administered orally, 50 mg twice daily, one Week on/one Week off, starting 7 days prior to cycle 1 day 1 ("impregnation phase"). JX-594 will be administered by intratumoral injection on day 1 of cycle 1, every 2 weeks, for a maximum of 4 injections. Number of subjects : 32
Intervention Type
Drug
Intervention Name(s)
Cyclophosphamide and JX-594 dose escalation
Other Intervention Name(s)
Brand name : ENDOXAN, Brand name: Pexa-Vec
Intervention Description
Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as designated by assigned dose-level, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.
Intervention Type
Drug
Intervention Name(s)
Cyclophosphamide and JX-594
Other Intervention Name(s)
Brand name : ENDOXAN, Brand name: Pexa-Vec
Intervention Description
Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as the dose recommended in the experimental phase I dose escalating study, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.
Intervention Type
Drug
Intervention Name(s)
Cyclophosphamide
Other Intervention Name(s)
Brand name : ENDOXAN
Intervention Description
Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off.
Intervention Type
Drug
Intervention Name(s)
Avelumab and JX-594 and Cyclophosphamide
Other Intervention Name(s)
Brand name: ENDOXAN, Brand name: Pexa-Vec, Brand name: Avelumab
Intervention Description
Avelumab will be administered by intravenous infusion (10 mg/kg) every 2 weeks, starting at Day 15 of cycle 1. Cyclophosphamide wil be administered bi-daily (50 mg x 2), starting 7 days prior to cycle 1 day 1 ("impregnation phase") and given on a week on/week off schedule. JX-594 will be administered by intratumoral injection (1 x109 p.f.u) on day 1 of cycle 1, every 2 weeks, for a maximum of 4 injections .
Primary Outcome Measure Information:
Title
Phase Ib : Maximum Tolerated Dose evaluated on the first cycle (D1 to D28) of the combination of JX-594 And metronomic cyclophosphamide
Description
the MTD is defined as the highest dose at which no more than 1 in 6 of the patients in the cohort experienced a DLT in the first treatment cycle
Time Frame
during the first cycle (28 days)
Title
Phase II : Advanced soft-tissue sarcoma: Assessment of the antitumor activity of the association of JX-594 and metronomic cyclophosphamide based on 6 month non-progression (CR, PR or SD more than 24 weeks) following RECIST v1.1 criteria
Description
Non-progression is defined as complete or partial response or stable disease, as per RECIST v1.1
Time Frame
Phase II : 6 months after the beginning of treatment
Title
Phase II : Advanced Breast cancer: Assessment of the antitumor activity of the association of JX-594 and metronomic cyclophosphamide Efficacy will be defined based on objective response under treatment (CR or PR) following RECIST v1.1 criteria
Description
Objective response is defined as complete or partial response as per RECIST v1.1
Time Frame
Phase II : 6 months after the beginning of treatment
Title
Phase II : Advanced soft-tissue sarcoma: Assessment of the antitumor activity of Avelumab in combination with IT JX-594 and metronomic cyclophosphamide based on 6 month non-progression (CR, PR or SD more than 24 weeks) following RECIST v1.1 criteria
Description
Non-progression is defined as complete or partial response or stable disease, as per RECIST v1.1
Time Frame
Phase II : 6 months after the beginning of treatment
Title
Phase II : Advanced Breast cancer: Assessment of the antitumor activity of avelumab in combination with IT JX-594 and metronomic cyclophosphamide Efficacy will be defined based on objective response under treatment following RECIST v1.1 criteria
Description
Objective response is defined as complete or partial response as per RECIST v1.1
Time Frame
Phase II : 6 months after the beginning of treatment
Secondary Outcome Measure Information:
Title
Phase Ib : Recommended Phase II dose (RP2D) of the association of JX-594 and metronomic cyclophosphamide
Description
Data from all cycles will be used to define the dose level of JX-594 to be recommended for further investigations in phase II
Time Frame
Phase Ib : Throughout the 6 months of treatment period
Title
Phase Ib: Objective response under treatment as per RECIST V1.1
Description
Objective response is defined as complete or partial response as per RECIST v1.1
Time Frame
an average of 6 months
Title
Phase Ib: Best overall response as per RECIST V1.1
Description
- Best overall response is defined as the best response recorded from the start of the study treatment until the end of treatment taking into account any requirement for confirmation (as per RECIST v1.1).
Time Frame
an average of 6 months
Title
Phase Ib: 6-months non-progression as per RECIST V1.1
Description
Non-progression is defined as complete or partial response or stable disease, as per RECIST v1.1
Time Frame
6-months after the beginning of treatment
Title
Phase Ib: 1-year progression-free survival as per RECIST V1.1
Description
PFS defined as the time from study treatment initiation to the first occurrence of disease progression or death (of any cause)
Time Frame
1-year after the beginning of treatment
Title
Phase Ib: 2-year progression-free survival as per RECIST V1.1
Description
PFS defined as the time from study treatment initiation to the first occurrence of disease progression or death (of any cause)
Time Frame
2-year after the beginning of treatment
Title
Phase Ib : Pharmacokinetics (PK): PK measurements expressed as Area Under the curve forJX-594
Time Frame
Day 8 of cycle 1, Day 15 of cycle 1, Day 22 of cycle 1, Day 1 of cycle 2, Day 8 of cycle 2, Day 22 of cycle 2, Day 8 of cycle 3, Day 8 of cycle 4, Day 8 of cycle 6 (Each cycle = 28 days)
Title
Phase Ib : Pharmacokinetics (PK): PK measurements expressed as half-life forJX-594
Time Frame
Day 8 of cycle 1, Day 15 of cycle 1, Day 22 of cycle 1, Day 1 of cycle 2, Day 8 of cycle 2, Day 22 of cycle 2, Day 8 of cycle 3, Day 8 of cycle 4, Day 8 of cycle 6 (Each cycle = 28 days)
Title
Phase Ib : Pharmacokinetics (PK): PK measurements expressed as Concentration peak forJX-594
Time Frame
Day 8 of cycle 1, Day 15 of cycle 1, Day 22 of cycle 1, Day 1 of cycle 2, Day 8 of cycle 2, Day 22 of cycle 2, Day 8 of cycle 3, Day 8 of cycle 4, Day 8 of cycle 6 (Each cycle = 28 days)
Title
Phase Ib : Dose-Limiting toxicity of the association of JX-594 and metronomic cyclophosphamide
Time Frame
during the first cycle (cycle = 28 days)
Title
Phase Ib : Predictive biomarkers analysis (cytokines levels)
Time Frame
baseline, day 8 of cycle 1, day 22 of cycle 1, day 8 of cycle 2, day 8 of cycle 4, day 8 of cycle 6. Each cycle = 28 days
Title
Phase Ib : Predictive biomarkers analysis (lymphocytes levels)
Time Frame
baseline, day 8 of cycle 1, day 22 of cycle 1, day 8 of cycle 2, day 8 of cycle 4, day 8 of cycle 6. Each cycle = 28 days
Title
Phase II : Best overall response defined as per RECIST v1.1 criteria
Description
Best overall response is defined as the best response recorded from the start of the study treatment until the end of treatment taking into account any requirement for confirmation (as per RECIST v1.1).
Time Frame
an average of 6 months
Title
Phase II : For sarcoma only: objective response following CHOI criteria
Time Frame
an average of 6 months
Title
Phase II : For sarcoma only: best overall response following CHOI criteria
Time Frame
an average of 6 months
Title
Phase II : For sarcoma only: 6- month non-progression following CHOI criteria
Time Frame
6-months after the beginning of treatment
Title
Phase II : 1-year Progression-Free Survival (PFS) defined as the time from study treatment initiation to the first occurrence of disease progression or death (of any cause), whichever occurs first
Description
PFS defined as the time from study treatment initiation to the first occurrence of disease progression or death (of any cause)
Time Frame
one year after the beginning of treatment
Title
Phase II : 2-year Progression-Free Survival (PFS) defined as the time from study treatment initiation to the first occurrence of disease progression or death (of any cause), whichever occurs first
Description
PFS defined as the time from study treatment initiation to the first occurrence of disease progression or death (of any cause)
Time Frame
two years the beginning of treatment
Title
Phase II : 1-year Overall Survial (OS) defined as the time from study treatment initiation to death (of any cause)
Description
OS defined as the time from study treatment initiation to death (of any cause)
Time Frame
one year after the beginning of treatment
Title
Phase II : 2-year Overall Survial (OS) defined as the time from study treatment initiation to death (of any cause)
Description
OS defined as the time from study treatment initiation to death (of any cause)
Time Frame
two year after the beginning of treatment
Title
Phase II : Toxicity graded using the common toxicity criteria from the NCI v4.0
Description
assessef with NCI-CTCAE V4
Time Frame
an average of 6 months
Title
Predictive biomarkers (cytokines level)
Time Frame
baseline, day 8 of cycle 1, day 22 of cycle 1, day 8 of cycle 2, day 8 of cycle 4, day 8 of cycle 6. Each cycle = 28 days
Title
Predictive biomarkers (lymphocytes level)
Time Frame
baseline, day 8 of cycle 1, day 22 of cycle 1, day 8 of cycle 2, day 8 of cycle 4, day 8 of cycle 6. Each cycle = 28 days
Title
Phase II : Relationship between levels of anti-JX-594 antibodies and efficacy of CP + JX-594 in terms of 6-month non progression for sarcoma (as per RECIST V1.1)
Time Frame
Six months after the beginning of treatment
Title
Phase II : Relationship between levels of anti-JX-594 antibodies and efficacy of CP + JX-594 in terms of objective response for breast cancer (as per RECIST V1.1)
Time Frame
an average of 6 months
Title
Phase II : Relationship between activation of the pRB/E2F/TK pathway and efficacy of CP + JX-594 on available archived tumor tissue in terms of 6- month non progression for sarcoma (as per RECIST V1.1)
Time Frame
Phase II : Six months after the beginning of treatment
Title
Phase II : Relationship between activation of the pRB/E2F/TK pathway and efficacy of CP + JX-594 on available archived tumor tissue in terms objective response for breast cancer (as per RECIST V1.1)
Time Frame
an average of 6 months
Title
Phase II Soft-tissue sarcoma: antitumor actiivty of avelumab in combination with IT JX-594 and metronomic CP in terms of best overall response
Description
- Best overall response is defined as the best response recorded from the start of the study treatment until the end of treatment taking into account any requirement for confirmation (as per RECIST v1.1)
Time Frame
an average of 6 months
Title
Phase II Breast cancer: antitumor actiivty of avelumab in combination with IT JX-594 and metronomic CP in terms of best overall response
Description
- Best overall response is defined as the best response recorded from the start of the study treatment until the end of treatment taking into account any requirement for confirmation (as per RECIST v1.1)
Time Frame
an average of 6 months
Title
Phase II Breast cancer: antitumor actiivty of avelumab in combination with IT JX-594 and metronomic CP in terms of 6-month non-progression
Description
Non-progression is defined as complete or partial response or stable disease, as per RECIST v1.1
Time Frame
6 months
Title
Phase II Soft-tissue sarcoma: antitumor actiivty of avelumab in combination with IT JX-594 and metronomic CP in terms of objective response Under treatment
Description
Objective response is defined as complete or partial response as per RECIST v1.1
Time Frame
an average of 6 months
Title
Phase II Soft-tissue sarcoma: antitumor actiivty of avelumab in combination with IT JX-594 and metronomic CP in terms of 1-year progression-free survival
Description
PFS defined as the time from study treatment initiation to the first occurrence of disease progression or death (of any cause)
Time Frame
1 year
Title
Phase II Breast cancer: antitumor actiivty of avelumab in combination with IT JX-594 and metronomic CP in terms of 1-year progression-free survival
Description
PFS defined as the time from study treatment initiation to the first occurrence of disease progression or death (of any cause)
Time Frame
1 year
Title
Phase II Soft-tissue sarcoma: antitumor actiivty of avelumab in combination with IT JX-594 and metronomic CP in terms of 2-year progression-free survival
Description
PFS defined as the time from study treatment initiation to the first occurrence of disease progression or death (of any cause)
Time Frame
2 years
Title
Phase II Breast cancer: antitumor activity of avelumab in combination with IT JX-594 and metronomic CP in terms of 2-year progression-free survival
Description
PFS defined as the time from study treatment initiation to the first occurrence of disease progression or death (of any cause)
Time Frame
2 years
Title
Phase II Soft-tissue sarcoma: antitumor activity of avelumab in combination with IT JX-594 and metronomic CP in terms of 1-year overall survival
Description
OS defined as the time from study treatment initiation to death (of any cause)
Time Frame
1 year
Title
Phase II Breast cancer: antitumor activity of avelumab in combination with IT JX-594 and metronomic CP in terms of 1-year overall survival
Description
OS defined as the time from study treatment initiation to death (of any cause)
Time Frame
1 year
Title
Phase II Soft-tissue sarcoma: antitumor activity of avelumab in combination with IT JX-594 and metronomic CP in terms of 2-year overall survival
Description
OS defined as the time from study treatment initiation to death (of any cause)
Time Frame
2 year
Title
Phase II Breast cancer: antitumor activity of avelumab in combination with IT JX-594 and metronomic CP in terms of 2-year overall survival
Description
OS defined as the time from study treatment initiation to death (of any cause)
Time Frame
2 year
Title
Phase II Soft-tissue sarcoma: safety profile of avelumab in combination with IT JX-594 and metronomic CP
Description
Safety profile will be assessed as per NCI-CTCAE v5
Time Frame
throughout the treatment period, an expected average of 6 months
Title
Phase II breast cancer: safety profile of avelumab in combination with IT JX-594 and metronomic CP
Description
Safety profile will be assessed as per NCI-CTCAE v5
Time Frame
throughout the treatment period, an expected average of 6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Main Inclusion Criteria: Histology: Phase Ib : Patient with histologically confirmed solid tumor Phase II : Patients with histologically confirmed HER2 negative breast cancer (treatment by CP+JX-594), or triple negative (treatment by avelumab + CP+JX-594) Patients with histologically confirmed soft tissue sarcoma confirmed by the RRePS Network, b)Progressive disease or relapse, after standard therapy according to RECIST v1.1 criteria diagnosed on the basis of two CT scan or MRI obtained at an interval less than 6 months in the period of 12 months prior to inclusion and confirmed by central review Metastatic or unresectable locally advanced disease Age ≥ 18 years ECOG ≤ 1 (Phase Ib), ≤ 2 (Phase II JX+CP) and ≤ 1 (Phase II avelumab+JX+CP). Life expectancy > 3 months, Measurable disease according to RECIST v1.1 outside any previously irradiated field. For patients treated by avelumab+JX+CP, at least one injectable site ≥ 2 cm and ≤ 8 cm in diameter and one distant non-injected measurable site (target site) At least three weeks since last chemotherapy, immunotherapy or any other pharmacological treatment and/or radiotherapy. Adequate hematological, renal, metabolic and hepatic functions. Women of childbearing potential must have a negative serum pregnancy test before study entry. Both women and men must agree to use a medically acceptable method of contraception throughout the treatment period and for six months after discontinuation of treatment. Patients informed of risks regarding drug interactions: patients receiving any substances that are inhibitors or inducers of CYP450 2B6 are ineligible Voluntarily signed and dated written informed consent prior to any study specific procedure. Patients with a social security in compliance with the French law. Main Exclusion Criteria: Previous treatment with JX-594 or other vaccina vector based treatment . Concomitant diseases/conditions (non exhaustive list): Clinically significant immunodeficiency, such as HIV or active Hepatite B or C Any other major illness that, in the Investigator's judgment, will substantially increase the risk associated with the patient's participation in this study. History of severe exfoliative skins condition requiring systemic treatment for more than 4 weeks in the last two years. active autoimmune disease for patients treated by avelumab Active central nervous system metastasis (CNS) Participation to a study involving a medical or therapeutic intervention in the last 30 days. Previous enrolment in the present study. Patient unable to follow and comply with the study procedures because of any geographical, social or psychological reasons. Known hypersensitivity to any involved study drug or any of its formulation components. Use of steroids (any route of administration), interferon/pegylated interferon or ribavirin that cannot be discontinued within 14 days prior to any JX-594 dose. No prior malignancy except for the following: adequately treated basal or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage 1 or Stage 2 cancer from which the patient is currently in complete remission or any other cancer from which the patient has been disease-free for 3 years. Active cardiovascular disease, including but not limited to significant coronary artery disease (e.g. requiring angioplasty or stenting) or congestive heart failure within the preceding 12 months. (treatment by CP+JX) Inability to suspend treatment with anti-hypertensive medication for 48 hours prior to and 48 hours after all JX-594 treatments. Pulse oximetry O2 saturation < 90% at rest on room air. Experienced a severe systemic reaction or side-effect as result of previous smallpox vaccination. Cardiac disease: LVEF out of normal limits ; cumulative dose of anthracyclines in excess of 450 mg/m² Known urinary tract obstruction Household contact exclusions for patients enrolled: children< 1 year old ; People with skin disease (e.g., eczema, atopic dermatitis and related diseases…), Immunocompromised hosts (severe deficiencies in cell-mediated immunity, including AIDS, organ transplant recipients, hematologic malignancies) Vaccination within 4 weeks of the first dose of study treatment and while on trial is prohibited except for administration of inactivated vaccines.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Antoine ITALIANO, MD, PhD
Phone
+33 524071947
Email
a.italiano@bordeaux.unicancer.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Antoine ITALIANO, MD, PhD
Organizational Affiliation
Institut Bergonié
Official's Role
Study Chair
Facility Information:
Facility Name
Institut Bergonie
City
Bordeaux
ZIP/Postal Code
33076
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Antoine ITALIANO, MD, PhD
Phone
+33 524071947
Email
a.italiano@bordeaux.unicancer.fr

12. IPD Sharing Statement

Learn more about this trial

A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX)

We'll reach out to this number within 24 hrs